Insilico Medicine doses first patient in GENESIS-IPF-3, the world’s first phase III trial of a generative AI-driven innovative drug
Business Announcement
Updates every hour. Last Updated: 28-Oct-2026 21:17 ET (29-Oct-2026 01:17 GMT/UTC)
Insilico Medicine (“Insilico,” HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.
Senior urban development decision-makers have revealed there is currently little incentive to consider public health impacts when shaping towns and cities, according to a new study that highlights the potential of an innovative economic valuation tool to address the problem.
Efforts to prevent dementia may be placing too much responsibility on people’s choices while overlooking the wider social and environmental conditions that shape brain health, according to new Curtin University research published in The Lancet Public Health.
Nearly half of health boards in England are deliberately delaying care for patients by imposing minimum waiting times in an attempt to manage demand and control costs, reveals exclusive data published by The BMJ today.
Artificial intelligence (AI) is increasingly integrated in public health for disease surveillance, behavioral interventions, risk communication, and population health management. However, fragmented oversight and limited equity safeguards can allow AI systems to reinforce existing disparities and create new risks for marginalized populations. A recent analytical essay examines these challenges and outlines strategies for responsible AI use, including equity assessments, community-based validation, transparency, data sovereignty, and human oversight.
The pathogen Clostridioides difficile (C. diff) — a leading cause of hospital-acquired infections — must contend with a variety of threats inside the harsh environment of the gut to survive and grow. Researchers at Vanderbilt Health have now discovered a unique system C. diff uses to simultaneously sense and respond to two different threats: host-mediated nutrient deprivation and a microbiota-produced antibiotic compound. Their findings, published Sept. 8 in Science Signaling, suggest new therapeutic options for preventing and treating C. diff infections.
As our world continues to warm, a multidisciplinary group of researchers from the University of Exeter and the UK Health Security Agency encourage consideration of potential interactions between urban green spaces, vector-borne diseases, and climate change as we work to increase public health benefits and reduce risks.